- Home
- AUPH vs CLVT Comparison
AUPH vs CLVT Comparison
Compare AUPH & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | CLVT |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | Canada | United Kingdom |
| Employees | N/A | 12000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUPH | CLVT |
|---|---|---|
| Price | $14.25 | $2.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | ★ $17.25 | $3.22 |
| AVG Volume (30 Days) | 1.1M | ★ 5.7M |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $16.53 | N/A |
| Revenue Next Year | $16.24 | $2.12 |
| P/E Ratio | $7.06 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $6.83 | $1.66 |
| 52 Week High | $16.54 | $4.77 |
Technical Indicators
Market Signals| Indicator | AUPH | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 41.29 |
| Support Level | $13.52 | $1.66 |
| Resistance Level | $15.23 | $3.85 |
| Average True Range (ATR) | 0.45 | 0.15 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 36.73 | 1.14 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.